Pages that link to "Q33375482"
Jump to navigation
Jump to search
The following pages link to Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura (Q33375482):
Displaying 50 items.
- Advances in Diagnosis and Treatments for Immune Thrombocytopenia (Q26738630) (← links)
- The role of rituximab in adults with warm antibody autoimmune hemolytic anemia (Q26824280) (← links)
- Immune thrombocytopenia (Q26830918) (← links)
- Piecing together the humoral and cellular mechanisms of immune thrombocytopenia (Q27024841) (← links)
- Rituximab in the treatment of autoimmune haematological disorders (Q33378854) (← links)
- The effect of anti-CD40 ligand in immune thrombocytopenic purpura (Q33378961) (← links)
- Immune regulation by B cells and antibodies a view towards the clinic. (Q33381036) (← links)
- Nitric oxide in immune thrombocytopenic purpura (Q33382856) (← links)
- Therapeutic implications of T-cell clonopathy of unknown significance in chronic immune thrombocytopenic purpura (Q33383399) (← links)
- Pathobiology of secondary immune thrombocytopenia (Q33383468) (← links)
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project (Q33383576) (← links)
- New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura (Q33383894) (← links)
- The ITP syndrome: pathogenic and clinical diversity (Q33384235) (← links)
- Immune thrombocytopenic purpura: pathophysiology and treatment (Q33384324) (← links)
- The feature of TRGV and TRDV repertoire distribution and clonality in patients with immune thrombocytopenic purpura (Q33385552) (← links)
- Successful treatment with rituximab of refractory idiopathic thrombocytopenic purpura in a patient with Kabuki syndrome (Q33385702) (← links)
- Repeated courses of rituximab in chronic ITP: Three different regimens (Q33386117) (← links)
- Raised expression of APRIL in Chinese patients with immune thrombocytopenia and its clinical implications (Q33386608) (← links)
- Physiopathology of idiopathic thrombopenic purpura (Q33386864) (← links)
- Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia (Q33389335) (← links)
- Rituximab in immune thrombocytopenia: transient responses, low rate of sustained remissions and poor response to further therapy in refractory patients (Q33390837) (← links)
- Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters (Q33392868) (← links)
- Pathophysiology and therapeutic options in primary immune thrombocytopenia (Q33393732) (← links)
- TLR7 promotes Th1 polarization in immune thrombocytopenia (Q33394743) (← links)
- ITP: a historical perspective (Q33394791) (← links)
- Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus--a prospective pilot study (Q33395310) (← links)
- Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia (Q33395792) (← links)
- Favorable Response of Chronic Refractory Immune Thrombocytopenic Purpura to Mesenchymal Stem Cells (Q33395970) (← links)
- Immunologic effects of rituximab on the human spleen in immune thrombocytopenia (Q33396902) (← links)
- Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients (Q33397525) (← links)
- CD72 gene expression in immune thrombocytopenia (Q33398413) (← links)
- Effects of high-dose dexamethasone on regulating interleukin-22 production and correcting Th1 and Th22 polarization in immune thrombocytopenia (Q33399398) (← links)
- Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura (Q33400631) (← links)
- Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia (Q33401100) (← links)
- Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia (Q33402209) (← links)
- Management of children and adolescents with primary immune thrombocytopenia: controversies and solutions (Q33402387) (← links)
- Preoperative use of romiplostim in thrombocytopenic patients with chronic hepatitis C and liver cirrhosis (Q33402611) (← links)
- Defective regulatory B-cell compartment in patients with immune thrombocytopenia (Q33402659) (← links)
- Short- and long-term effects of rituximab for the treatment of thrombotic thrombocytopenic purpura: four case reports (Q33402749) (← links)
- Characterization of Th1- and Th2-associated chemokine receptor expression in spleens of patients with immune thrombocytopenia (Q33406481) (← links)
- Pathophysiology and management of primary immune thrombocytopenia (Q33407942) (← links)
- The effect of rituximab on vaccine responses in patients with immune thrombocytopenia (Q33409067) (← links)
- Cellular immune dysfunction in immune thrombocytopenia (ITP). (Q33409710) (← links)
- Aberrant frequency of IL-10-producing B cells and its association with Treg/Th17 in adult primary immune thrombocytopenia patients (Q33416700) (← links)
- A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP. (Q33419712) (← links)
- STAT1 single nucleotide polymorphisms and susceptibility to immune thrombocytopenia (Q33420638) (← links)
- Efficacy and Safety of Rituximab in Systemic Lupus Erythematosus and Sjögren Syndrome Patients With Refractory Thrombocytopenia: A Retrospective Study of 21 Cases (Q33424691) (← links)
- Mycophenolate mofetil therapy for severe immune thrombocytopenia (Q33424988) (← links)
- Identification of novel biomarkers in chronic immune thrombocytopenia (ITP) by microarray-based serum protein profiling (Q33428073) (← links)
- Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis (Q33428564) (← links)